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Gynecological infections, such as bacterial 
vaginosis (BV) are frequent [1] and carry 
a high psychological burden especially if 
recurrent [2] and infections with human 
papillomavirus (HPV) may have serious 
consequences, such as cervical carcinoma 
[3]. Epidemiological studies investigating 
such conditions should include cervico-
vaginal biosampling due to limitations of 
self-reported medical history and serolog-
ical detection [e.g. 4]; however, in popu-
lation-based general cohort studies that 
depend on long-term follow-up like the 
German National Cohort (GNC), any ex-
tra burden on participants has to be kept 
to a minimum. Hence, additional mod-
ules on infectious diseases should imple-
ment biosampling methods that can be 
conducted easily and preferably at home 
as self-sampling in order to minimize any 
additional time spent at the study center.
Most studies in a systematic review 
conducted in 2007 showed that self-sam-
pling of vaginal biomaterial for detection 
of HPV deoxyribonucleic acid (DNA) us-
ing a variety of techniques and tools was 
feasible, acceptable and adequate for anal-
ysis [5]. A more recent systematic review 
on the same topic from 2010 reaffirmed 
the finding that self-sampling is generally 
well perceived and easy for women to per-
form; however, the authors emphasized 
that methodological limitations, such as 
measurement error and selection bias 
could result in an overestimation of these 
findings [6]; but self-sampling is applica-
ble even in low-resource settings [7]. For 
Germany, Deleré et al. demonstrated that 
self-collection of cervicovaginal lavage is 
a valid approach for detection of HPV [8] 
and was also successfully used in a popu-
lation-based study in young female adults 
in Germany [9].
Adding cervicovaginal lavage to the in-
vestigations in the GNC would open un-
precedented opportunities to prospective-
ly investigate associations between cervi-
covaginal infection and colonization with 
a comprehensive phenotyping of non-in-
fectious diseases; however, given the age 
distribution of the GNC and the exten-
sive investigations on the participants (see 
Ahrens et al. in this issue), it is not clear 
to what extent such a self-collection ap-
proach is feasible within the GNC. This 
study therefore aimed to examine the fea-
sibility and acceptance of self-sampling of 
cervicovaginal lavage within the frame-
work of the GNC taking into account the 
biological quality of the samples and ap-
plicability of a new high-throughput di-
agnostic approach developed by Schmitt 
et al. [10]. Additionally, the results of all 
pathogen detections were to be evaluat-
ed considering the results in the literature 
from similar studies.
Methods
Study design, population 
and self-sampling
This cross-sectional study took place in 
two study centers (Hamburg and Ha-
nover) of the GNC during Pretest 2 (Sep-
tember 2012 to December 2012) (see 
Ahrens et al. in this issue) as an add-on 
module to the main program, which is 
described by Wichmann et al. [11]. Brief-
ly, 18 study centers in Germany will inter-
view and examine 200,000 men and wom-
en randomly selected from the population 
register. The examinations and interviews 
cover cardiovascular, metabolic, neuro-
logical and infectious diseases. In con-
cordance with the GNC, the age structure 
of the study population in Pretest 2 was 
aimed at 10 % for 20–29 and 30–39-year-
olds and 26.7 % for each of the age groups 
40–49, 50–59 and 60–69 years [11].
The analysis of this feasibility study is 
limited to Pretest 2 participants randomly 
sampled through the population registra-
tion office. Study participation was offered 
to all female participants recruited for 
Pretest 2 (n = 162) and accessible for add-
on modules. Pregnant women and wom-
en within 30 days after childbirth were 
excluded. Informed consent for this addi-
tional study on collecting a cervicovagi-
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nal lavage was obtained during the par-
ticipant’s visit to the study center. After re-
ceiving the sampling kit at the study cen-
ter, self-sampling was done at home. The 
tool applied (second generation Delphi 
ScreenerTM, Delphi Bioscience, BV Scher-
penzeel, The Netherlands) is a sterile in-
strument with 3 ml of physiological saline. 
After inserting the device into the vagina, 
followed by pushing a button at the end of 
the Screener, the lavage liquid is released 
into the vagina (near the cervix). The flu-
id is automatically reabsorbed by the de-
vice during removal from the vagina af-
ter the button is released. The participants 
then transferred the lavage into a trans-
portation tube and mailed it to the labo-
ratory (Charité, Berlin) where the HPV 
status of the samples was determined. Re-
sults were regularly reported back to the 
participants. After completion of recruit-
ment, testing for further microbes was do-
ne at the German Cancer Research Cen-
ter, Heidelberg, using sexually transmit-
ted infection profiling (STIP). Participants 
whose samples indicated the presence of 
Neisseria gonorrhoeae infection were rec-
ommended to immediately contact a gy-
necologist for confirmation by clinical di-
agnosis. If sample analysis by STIP result-
ed in any other suspicious findings partic-
ipants received a recommendation to see 
their gynecologist.
Questionnaire on acceptability
The questionnaire contained a question 
on sexual history (ever had sexual inter-
course: yes/no) and assessed the accept-
ability of sampling as consent (i.e. yes/
partly/no) to the following statements: 
“The acquisition of a vaginal lavage at 
home was acceptable for me.”, “It was easy 
to self-sample the specimen.”, “The sam-
pling was user-friendly.”, “The sampling 
was physically uncomfortable.”, “I consid-
er sampling of a vaginal lavage a violation 
of privacy.” and “It is more acceptable to 
sample a vaginal lavage at home than at 
a study center.”. Demographic data and 
medical history were collected during the 
main interview of the GNC.
DNA extraction and 
HPV genotyping
Total DNA was extracted using the Qia-
gen DNA mini kit (Hilden, Germany) and 
a broad spectrum GP5 + /GP6 + -based 
polymerase chain reaction (PCR) includ-
ing beta-globin was conducted as de-
scribed [12] followed by Luminex®-based 
HPV genotyping (multiplex HPV geno-
typing, Luminex, Austin TX [13]). For 
DNA sample validation a PCR for human 
beta-globin DNA was performed and 
products were separated and read on 2 % 
agarose gels. Only samples showing a spe-
cific product were considered to be DNA 
positive. The detection of HPV 6, 11, 16, 18, 
26, 31, 33, 35, 39, 42, 43, 45, 51, 52, 53, 54, 
56, 57, 58, 59, 66, 68, 70, 72, 73, 82 and 90 




The STIP was carried out as previously 
described [10]. Briefly, STIP is a multiplex 
PCR for microbial target sequences fol-
lowed by hybridization of the biotinylated 
amplimers to specific probes on fluores- 
cent beads (xMAP technology, Luminex®). 
The STIP is able to simultaneously identi-
fy Atopobium vaginae, Candida albicans, 
C. glabrata, C. krusei, Chlamydia tracho-
matis,  Gardnerella vaginalis, herpes sim-
plex virus (HSV) 1, HSV 2, Mycoplasma 
genitalium, M. hominis, M. pneumoniae, 
M. spermatophilum, Neisseria gonorrhoe-
ae, Treponema pallidum, Trichomonas 
vaginalis, Ureaplasma urealyticum and 
U. parvum, and the bacteria of the nor-
mal genital flora Lactobacillus iners. Oth-
er Lactobacillus species, including L. gas-
seri, L. crispaticus, L. jensenii and L. vagi-
nalis were detected together by a univer-
sal Lactobacillus probe. Additional Candi-
da species, e.g. C. parapsilosis and C. trop-
icalis, were detected by a universal Can-
dida probe. Presence of amplifiable hu-
man DNA was verified using the human 
DNA polymerase alpha (PolA) sequence 
as a target. The load of A. vaginae, G. vag-
inalis and Lactobacillus species was deter-
mined and a BV score using load ratios of 
either A. vaginae or G. vaginalis over Lac-
tobacillus was calculated as previously de-
scribed [10]. The score grades for BV were 
as follows: 0 absence of BV, 1 weak indi-
cation for BV, 2 some indications for BV, 
3–4 strong indications for BV and 5 very 
strong indications for BV. Likewise, can-
didiasis was determined by a ratio of sig-
nals from several Candida spp. probes and 
Lactobacillus as previously described [10]. 
In cases where signal intensities of patho-
gens and Lactobacillus were too low, BV 
and candidiasis could not be computed.
Definitions and statistical analysis
Migration status was defined according 
to Schenk et al. [14] as either both par-
ents not born in Germany or one parent 
not born in Germany and interviewee not 
living in Germany since birth or German 
not being native language. Household net 
equivalent income per month was calcu-
lated using midpoint estimates of group 
levels; the highest group (≥ 8000 €) was 
set at 10,000 €. To account for household 
size, weighting was done according to the 
German demographic standards [15] us-
ing the modified Organisation for Eco-
nomic Co-operation and Development 
(OECD) equivalence scale. Women were 
categorized according to their menstrua-
tion status as premenopausal versus per-
imenopausal/postmenopausal. For bac-
teria detected by STIP, a participant was 
included into the statistical analysis if at 
least one species of microbe was detect-
ed and amplified human DNA (PolA) was 
present. For samples without detection of 
any microbial agent, potential treatment 
with antibiotics was assumed [10] and 
these specimens were therefore exclud-
ed from the respective statistical analy- 
sis (bacteria). For the analysis regarding 
viruses, all samples were included as vi-
ruses are not affected by antibiotics. The 
age of participants was grouped in 10-year 
increments (e.g. 20–29 and 30–39 years). 
To test differences between groups for 
statistical significance (comparisons of 
participants and non-participants, of age 
groups and categories of acceptability, 
and of time elapsed until arrival of sam-
ples at the laboratory depending on HPV 
status), for nominal or ordinal variables 
χ2-test and Fisher’s exact test were used 
and for continuous variables the Mann-
Whitney test after evaluating observed 
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within the German National Cohort (Pretest 2)
Abstract
Background and objectives. Within the Ger-
man National Cohort (GNC) 100,000 adult 
women in Germany will be comprehensive-
ly interviewed and examined. While women’s 
health is addressed in the basic interview, di-
rect detection of cervicovaginal microbial col-
onisation or infection is not part of the exam-
ination protocol. In a pilot project the feasi-
bility of female study participants of the GNC 
collecting a cervicovaginal lavage at home 
without having to involve a gynecologist or 
other medical personnel was thus investigat-
ed. The ability of the procedure to detect vag-
inal microbes and conditions including hu-
man papillomavirus (HPV), Chlamydia tracho-
matis and bacterial vaginosis (BV) were al-
so explored.
Methods. This cross-sectional study was 
conducted in two study centers (Hamburg 
and Hanover) of the GNC during Pretest 2 in 
2012 as an add-on module to the main pro-
gram of the National Cohort. Participants 
were randomly selected through the popula-
tion registration office. After providing writ-
ten informed consent at the study center, 
participants self-collected a cervicovaginal la-
vage (Delphi ScreenerTM) at home following 
written instructions. Participants mailed sam-
ples and acceptability questionnaires to the 
laboratory and the study center, respective-
ly. Acceptability of self-sampling was catego-
rized as consent, partial consent and rejec-
tion. The samples were analyzed by multiplex 
HPV genotyping for the presence of 27 mu-
cosal HPV subtypes. To detect other patho-
gens “Sexually Transmitted Infection Profil-
ing” (STIP) was used, a novel multiplex poly-
merase chain reaction (PCR) for various vag-
inally occurring pathogens/conditions cou-
pled with subsequent bead-based Luminex® 
hybridization. Human beta-globin and DNA 
polymerase alpha (PolA) sequences were 
used as positive controls for the detection of 
human DNA during HPV detection and STIP, 
respectively.
Results. The participation based on the pro-
portion of all women in Pretest 2 who could 
take part in the add-on Pretest 2 was 67.3 % 
(109 out of 162). The age of participants 
ranged from 20 to 69 years. The self-report-
ed median duration of the collection of the 
lavage was 5 min. Analysis of the question-
naires (n = 108) revealed that the self-sam-
pling of a cervicovaginal lavage was accept-
able to 98 % of women (106 out of 108), and 
considered to be easy by 89 % (96 out of 108) 
as well as user-friendly by 96 % of the wom-
en (104 out of 108). Human beta-globin and 
PolA as markers for human DNA and sample 
quality were detected in all samples analyzed 
while HPV as a marker for pathogen detect-
ability was identified in 18 out of 109 sam-
ples. Of the 107 samples tested with STIP as a 
second marker for pathogen detectability, 5 
samples were excluded from statistical analy-
ses on bacterial colonization because of signs 
in the laboratory results of the use of antibi-
otics. For the computation of the possible oc-
currence of bacterial vaginosis and candidi-
asis 7 and 8 samples, respectively, were ex-
cluded because of low signal intensities re-
sulting in an evaluation of 95 or 94 samples, 
respectively. Ureaplasma parvum was detect-
ed in 22 out of 102 samples, BV in 14 out of 
95 samples and candidiasis in 13 out of 94 
samples. Chlamydia trachomatis was not de-
tected in any sample.
Conclusion. The feasibility study on cervico-
vaginal self-sampling indicates that this form 
of biosampling was very well accepted with-
in the framework of the GNC and feasible in 
terms of pathogen detection. Its further ap-
plication in the GNC would allow investiga-
tion of transience and persistence, or long-
term effects of vaginal (co)infections and col-
onization.
Keywords
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Machbarkeit und Akzeptanz von cervicovaginaler Selbstbeprobung 
in der Nationalen Kohorte (Pretest 2)
Zusammenfassung
Hintergrund und Ziele. In der Nationalen 
Kohorte (NAKO) werden 100.000 erwachse-
ne Frauen in Deutschland umfassend befragt 
und untersucht werden. Während Frauenge-
sundheit im Basisinterview thematisiert wird, 
ist der direkte Erregernachweis von cervico-
vaginalen mikrobiellen Besiedlungen oder In-
fektionen nicht Teil des Untersuchungsproto-
kolls. In einem Pilotprojekt untersuchten wir 
daher die Machbarkeit der häuslichen Selbst-
entnahme einer cervicovaginalen Lavage 
durch Studienteilnehmerinnen der NAKO oh-
ne Kontakt zu einem Frauenarzt oder ande-
rem medizinischen Personal. Wir explorierten 
außerdem die Möglichkeit bei diesem Vor-
gehen, verschiedene vaginal auftretende Er-
reger und Erkrankungen, inklusive humane 
Papillomviren (HPV), Chlamydia trachomatis 
und bakterielle Vaginose (BV) nachzuweisen.
Methoden. Wir führten die Studie als Quer-
schnittsstudie 2012 während Pretest 2 als zu-
sätzliches Modul zum Hauptprogramm der 
NAKO in zwei Studienzentren (Hamburg und 
Hannover) durch. Die Teilnehmerinnen ent-
stammen einer zufällig gezogenen Einwoh-
nermeldeamtstichprobe. Sie führten nach 
Aufklärung und schriftlicher Einverständnis-
erklärung im Studienzentrum auf Basis einer 
schriftlichen Anweisung die Probenentnah-
me zuhause durch (Delphi ScreenerTM). Die 
Proben und Akzeptanzfragebögen wurden 
per Post von den Teilnehmerinnen direkt an 
das Labor bzw. an das jeweilige Studienzen-
trum gesandt. Akzeptanz wurde in drei Kate-
gorien abgefragt: Zustimmung, teilweise Zu-
stimmung, Ablehnung. Die Proben wurden 
per Multiplex-Papillomvirusgenotypisierung 
auf Anwesenheit von 27 mukosalen HPV-Ty-
pen untersucht. Der Nachweis anderer Patho-
gene erfolgte durch „Sexually Transmitted In-
fection Profiling“ (STIP), einer neuen Multi-
plex- Polymerase-Kettenreaktion (PCR) für 
verschiedene vaginal auftretende Erreger/Er-
krankungen mit anschließender „Bead“-ba-
sierter Luminex®-Hybridisierung. Als Positiv-
kontrolle wurden ß-Globin (HPV-Nachweis) 
und die humane DNA Polymerase alpha (Po-
lA)-Sequenz (STIP) nachgewiesen.
Ergebnisse. Die Teilnahme als Anteil an al-
len Frauen in Pretest 2, die an Zusatzmodulen 
in den betreffenden Studienzentren teilneh-
men konnten, lag bei 67,3 % (109/162). Die 
Altersspanne der Probandinnen reichte von 
20 bis 69 Jahre. Im Median dauerte die Pro-
benentnahme nach Angaben der Probandin-
nen 5 Minuten. Die Analyse der Akzeptanz-
fragebögen (n = 108) ergab, dass die selbst-
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data regarding normal distribution us-
ing graphical tools and the Shapiro-Wilk 
test. All statistical tests were 2-sided and a 
p-value < 0.05 was considered statistical-
ly significant. Proportions were calculat-
ed with missing or unspecified values as 
an additional category, whereas statistical 
tests were performed without this catego-
ry. Approximate binomial confidence in-
tervals (CI) were calculated based on the 
formula given in [16] using Excel (Micro-
soft, Redmond WA). For all other statis- 
tical analyses STATA 12 (StataCorp LP, 
College Station TX) was used.
Results
Participation
Of the 162 women initially recruited for 
Pretest 2 from a random registration of-
fice sample, 1 woman was excluded due to 
pregnancy and 126 (77.8 %) agreed to par-
ticipate in the additional module on cervi-
covaginal lavage, from whom 109 (86.5 %) 
samples and 108 (85.7 %) completed ques-
tionnaires were received (. Fig. 1). The 
participation in the add-on module with-
in Pretest 2 of the GNC was thus 67.3 % 
(109 out of 162, 95 % CI 59.7; 74.0).
Characteristics of participating and 
non-participating women are presented 
in . Table 1. A significant difference be-
tween both groups was detected with re-
spect to hysterectomy. The median age 
of participating women was 5 years low-
er than that of non-participating women 
(no significant difference) (. Table 1).
Timing
The median time from the visit at the 
study center to sampling was 7 days 
(n = 107, interquartile range (IQR) 3–16 
days, range 0–90 days). Median reported 
duration of sampling was 5 min (n = 105, 
IQR 3–6 min, range 1–30 min). It took a 
median time of 2 days (n = 102, IQR 2–4 
days, range 1–140 days) after self-sam-
pling for the specimens to arrive at the 
laboratory. There was no significant dif-
ference in this respect between HPV pos-
itive and negative samples (identical me-
dian, p = 0.13).
Acceptance
A total of 98.1 % (106/108, 95 % CI 93.5; 
99.5) judged the sampling of a cervico-
vaginal lavage at home to be acceptable, 
88.9 % (96/108, 95 % CI 81.6; 93.5) as easy 
and 96.3 % (104/108, 95 % CI 90.9; 98.6) 
as user-friendly. Only 6.5 % reported a 
physically uncomfortable feeling during 
sampling (7/108, 95 % CI 3.2; 12.8) and 
10.2 % (11/108, 95 % CI 5.8; 17.3) stated 
“partly” for this item. Self-sampling of a 
cervicovaginal lavage was seen as no vio-
lation of privacy by 82.4 % (89/108, 95 % 
CI 74.2; 88.4) and was preferably done 
at home instead of at the study center in 
78.7 % of cases (85/108, 95 % CI 70.1; 85.4) 
(. Fig. 2).
No statistically significant differenc-
es could be detected between age groups 
and any of the aforementioned categories 
of acceptability with the exception of the 
item on privacy violation (here p = 0.02, 
n = 108); other results of Fisher’s exact 
test for comparison of each category and 
age groups: acceptance p = 0.2 (n = 108), 
easiness p = 0.86 (n = 107), user-friendli-
ness p = 0.87 (n = 108), physical discom-
fort p = 0.26 (n = 107) and preferred place 
of sampling p = 0.63 (n = 108).
With respect to age categories, sam-
pling a cervicovaginal lavage was viewed 
as no violation of privacy by 57.1 % 
(4/7) of 20–29-year-olds, by 60.0 % 
(9/15) of 30–39-year-olds, 82.1 % (23/28) 
of 40–49-year-olds, 87.1 % (27/31) of 
50–59-year-olds and 96.3 % (26/27) of 
60–69-year-olds.
Two minor adverse events without the 
necessity to contact a doctor were report-
ed (i.e. slightly painful sensation in low-
er abdomen after sampling). Three wom-
en aged between 32 and 65 years stated no 
previous sexual intercourse; all of whom 
assessed the sampling as acceptable and 
user-friendly, 2 as easy, physically not un-
comfortable and as no violation of privacy.
Human beta-globin DNA was detect-
ed in all samples (n = 109) and HPV DNA 
was identified in 18 out of 109 samples: 10 
different genotypes were found (HPV11, 
16, 26, 31, 39, 42, 54, 57, 66, and 68) and 
6 out of 18 HPV positive women were in-
fected with at least 2 genotypes. HPV16 
was found in 6 out of 18 positive samples 
and all other genotypes were detected less 
often.
Two samples arrived too late to be in-
cluded in the STIP (n = 107). PolA DNA 
quality was sufficient for analysis of all 
samples analyzed by STIP; five samples 
were excluded from statistical analyses of 
bacterial occurrence because no microbes 
could be detected by STIP which was in-
terpreted as potential antibiotic use. The 
bacteria A. vaginae, U. parvum, Candida 
spp., C. albicans, G. vaginalis, M. genita-
lium, M. hominis, M. spermatophilum, C. 
ständige Durchführung einer cervicovagina-
len Lavage für 98 % der Frauen akzeptabel war 
(106/108), dass 89 % die Probenentnahme als 
leicht (96/108) und 96 % als benutzerfreund-
lich einstuften (104/108). Beta-Globin und Po-
lA als Marker für humane DNA und Proben-
qualität konnte bei allen untersuchten Proben 
nachgewiesen werden, während HPV als Mar-
ker für Pathogenerfassbarkeit in 18 von 109 
Proben nachgewiesen wurde. Von 107 mit-
tels STIP als zweitem Marker für Pathogener-
fassbarkeit untersuchten Proben wurden 5 von 
den statistischen Analysen bakterieller Erreger 
aufgrund von Hinweisen in den Laboranalysen 
auf Antibiotikaeinnahme ausgeschlossen. Um 
zu berechnen, ob bakterielle Vaginose oder 
Candidose vorhanden sind, wurden 7 bzw. 8 
Proben aufgrund niedriger Signalintensitäten 
ausgeschlossen. Dies führte zur Evaluierung 
von 95 bzw. 94 Proben. Wir konnten z.B. Ure-
aplasma parvum in 22 von 102 Proben nach-
weisen, bakterielle Vaginose in 14 von 95 Pro-
ben und Candidose in 13 von 94 Proben. Chla-
mydia trachomatis konnte in keiner Probe de-
tektiert werden.
Schlussfolgerung. Unsere Machbarkeitsstu-
die zur cervicovaginalen Probenselbstentnah-
me zeigt, dass diese Bioprobengewinnung im 
Kontext der NAKO sehr gut akzeptiert wurde 
und hinsichtlich Pathogennachweisen mach-
bar ist. Die zukünftige Anwendung in der Na-
tionalen Kohorte würde es ermöglichen, Trans-
ienz/Persistenz oder langfristige Effekte vagi-
naler (Ko-) Infektionen und Kolonisationen zu 
untersuchen.
Schlüsselwörter
Selbstbeprobung · Akzeptanz · Nationale 
Kohorte (NAKO) · Cervicovaginale Lavage · 
Humane Papillomviren (HPV)
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krusei, and N. gonorrhoeae were detected 
(. Table 2). In the case of pathogen and 
Lactobacillus intensities being too low, BV 
(n = 7) and candidiasis (n = 8) could not be 
computed. Evidence for BV was present 
in 14 out of 95 of specimens, of which 9 
had a BV score of 2 (i.e. some indications 
for BV) and 5 a score of 4–5 (strong and 
very strong indications for BV). Candidi-
asis was detected in 13 out of 94 samples 
and BV, U. parvum; and candidiasis oc-
curred in all age groups (data not shown).
Discussion
In this feasibility study it could be shown 
that participation in an add-on module on 
self-sampling of a cervicovaginal lavage 
within the GNC was sufficient to design a 
future study based on the tested approach 
for the main phase of the GNC. Accept-
ability of self-sampling at home was high 
among the female Pretest 2 participants 
in Hanover and Hamburg. The high ac-
ceptability of the device used for self-
sampling is in line with a German study 
among 20–30-year-old women routinely 
screened by gynecologists in which partic- 
ipants reported the device as being easy to 
use and were fine regarding sensation [8]. 
In a population-based prevalence study 
among 20–25-year-old women conduct-
ed by Deleré et al. 73.4 % of the partici-
pants stated that self-sampling was easy 
or very easy [9]. In The Netherlands, the 
device has already successfully been used 
in a trial on cervical screening comparing 
self-sampling and regular screening by 
physicians [17]. Other devices for vaginal 
self-sampling, such as swabs have been ef-
fectively used in epidemiological and clin-
ical studies (e.g. [18]), mainly within the 
context of cervical cancer screening [5].
In addition, it could be shown that self-
sampling of a cervicovaginal lavage is al-
so acceptable and applicable within the 
GNC, where women are typically older 
than in most previously cited studies and 
also already involved in an extensive pro-
tocol of epidemiological examinations. It 
is of note that willingness to participate 
was less likely among older women and 
among those with a hysterectomy. The 
latter might partly be a result of HPV in-
fection being emphasized during some of 
the preconsent counselling and feedback 
of results, which may have been of less in-
terest to women after hysterectomy. In fu-
ture similar studies among older women, 
participants should be informed about the 
respective benefits of participation. With 
respect to acceptability, the only signifi-
cant association with age was that young-
er women more frequently felt that their 
privacy during the self-sampling was af-
fected than older women; however- over-
all, participants were still younger than 
non-participants. With respect to oth-
er effects of age on categories of accept-
ability, the power of this study might not 
be sufficient to determine any addition-
al statistically significant differences. The 
fact that participants were younger than 
non-participants suggests that selection 
bias could be present in this study; there-
fore, the study results could overestimate 
acceptability.
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Questionnaires n=108 Biosamples n=109
No return of sample and questionnaire:
n=17
Not elegible n=1 (pregnant)
Not willing to participate in add-on study
on cervicovaginal lavage: n=35
Fig. 1 9 Flow chart 



































































of acceptability of pro-
cedure and device 
used for biosampling 
(n = 108)
 
The results of this study show that the 
chosen approach generates high quali-
ty biospecimens that allow molecular bi-
ological detection of various vaginal mi-
crobes. There were no statistically signif-
icant differences in the time elapsed until 
the biosamples arrived in the laboratory 
depending on HPV status; however, the 
statistical power of the study might not 
be sufficient to detect a difference. The 
most common genotype could be con-
firmed as HPV 16 [3, 9, 19] but less fre-
quent HPV genotypes could also be de-
tected. The detection of HPV and other 
colonizing agents was done (a) as an in-
centive for the women to participate, (b) 
to evaluate the quality of the biosamples 
and (c) to assess the study in comparison 
to similar studies. The small sample size 
does not therefore allow a thorough inter-
pretation of the results concerning preva-
lence of HPV, BV, candidiasis and any of 
the other pathogens detected using STIP.
Deleré et al. used the same sampling 
device and HPV detection method and 
reported an HPV prevalence of 38.1 % 
among non-vaccinated 20–25-year-olds 
[9]. The age-specific estimate is similar 
(data not shown); however, the very small 
sample size of this age group considerably 
limits this comparison. The concordance 
between the studies could also be due to 
chance.
Due to the use of different tests with 
different numbers of genotypes, compar-
isons with other studies regarding non-
genotype-specific prevalence are only 
suitable to a limited extent: For example, 
a German study by Klug et al. recruiting 
women over the age of 30 years within the 
context of routine cervical cancer screen-
ing, having specimens taken by physi- 
cians and using Hybrid Capture 2 as a 
screening test, reported an overall HPV 
prevalence of 5 % (30–39 years 6.9 % to 
60 + years 2.5 %) which is lower than the 
results of this study [19]. This might be 
the case because the HPV detection meth-
od used in this study identified a greater 
number of HPV genotypes. In addition, 
the recruitment strategies in both stud- 
ies differed (women participating in gy-
necological screening in Klug et al. [19] 
versus random sample from the registra-
tion office in this study) which might lead 
to diverse results. Women taking part in 
this study might have suspected a HPV 
infection potentially leading to selection 
bias and more HPV detection. In gener-
al, selection bias could distort estimates of 
positive testing in either direction in this 
study.
Within this add-on module the ap-
plicability of a new high-throughput di-
agnostic approach in the general popula-
tion was also tested [10]. Detection of BV 
was only slightly lower than in other pop-
ulation-based studies in developed coun-
tries among Caucasian women (e.g. [1]).
C. albicans was the most common sin-
gly identified Candida species which is in 
line with reports from the literature [20]. 
Chlamydia trachomatis, like several other 
sexually transmitted pathogens, was not 
identified within this study population. 
This could be due to the small sample size 
but also due to the participants’ age being 
mostly over 40 years. Furthermore, some 
of these pathogens may be more prevalent 
in other parts of the genital tract because 
of the ascension to the upper genital tract 
and might therefore not be sampled with 
the device used in this study.
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Table 1 Characteristics of participantsa versus women with no participationb
Variable Category Total Participation No participation P-value*
n = 161 n = 109 n = 52
Age (years) Median (min; max) 53 (20; 69) 51 (20; 69) 56 (21; 69) 0.06
Age groups
n (%)
20–29 years 11 (6.8) 7 (6.4) 4 (7.7) 0.33
30–39 years 18 (11.2) 15 (13.8) 3 (5.8)
40–49 years 37 (23.0) 28 (25.7) 9 (17.3)
50–59 years 49 (30.4) 31 (28.4) 18 (34.6)




No 135 (83.9) 89 (81.7) 46 (88.5) 0.17
Yes 25 (15.5) 20 (18.3) 5 (9.6)





≤ 1500€ 45 (28.0) 30 (27.5) 15 (28.8) 0.82
1500 < x ≤ 3000€ 77 (47.8) 51 (46.8) 26 (50.0)




Premenopausal 50 (31.1) 38 (34.9) 12 (23.1) 0.13
Perimenopausal/
postmenopausal




No 128 (79.5) 93 (85.3) 35 (67.3) 0.008
Yes 33 (20.5) 16 (14.7) 17 (32.7)
aMailed questionnaire and biosample or biosample only
bDid not give informed consent for the study or did not return the questionnaire and/or biosample
*χ2-test or Fisher’s exact test, except for age as continuous variable (Mann-Whitney test)
Table 2 Pathogens and conditions de-
tected by sexually transmitted infection 
profiling (STIP)
Pathogen/condition n
n = 107, all samples analyzed by STIP
Herpes simplex virus 1 0
Herpes simplex virus 2 0

















Other Candida spp. 21
n = 95, additional exclusion of 7 samples (low 
signals)
Bacterial vaginosis 14
n = 94, additional exclusion of 8 samples (low 
signals)
Candidiasis 13
These results should be interpreted 
with caution as STIP is a newly developed 
method, albeit shown to be accurate and 
robust [10]. Furthermore, the number of 
analyzed biosamples was not designed 
to detect less common pathogens of the 
genital tract or calculate age-specific esti-
mates so that all results regarding patho-
gens should only be interpreted as mark-
ers for detectability.
Conclusions
This study shows that self-sampling of a 
cervicovaginal lavage at home indepen-
dently of a gynecological examination 
is highly accepted among participants 
of the GNC and generates high quali-
ty specimens that allow nucleic acid am-
plification tests for pathogen detection. 
This opens a promising opportunity to 
study the occurrence of genital infection 
and colonization in the context of a com-
prehensive phenotyping of highly preva-
lent non-infectious diseases in a prospec-
tive and population-based cohort de-
sign. Given the public health importance 
of research questions resulting from this 
opportunity it is strongly recommended 
that self-sampling of cervicovaginal la-
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